Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 8Sinonasal undifferentiated carcinoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Leukemia, Myeloid 1Leukemia, Monocytic, Acute 1Leukemia 1Esthesioneuroblastoma, Olfactory 1Chondrosarcoma 1

Interventions

fludarabine 4fludarabine phosphate 3asciminib 3venetoclax 2gilteritinib 2Whole-Body Irradiation 2Tacrolimus 2Idarubicin 2Cytarabine 2Cyclophosphamide 2Busulfan 2Bone Marrow Transplantation 2ponatinib 1nilotinib 1enasidenib 1blinatumomab 1aldesleukin 1Thiotepa 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Mycophenolic Acid 1Methotrexate 1Mesna 1Melphalan 1Interleukin-2 1Imatinib Mesylate 1Hyperbaric Oxygenation 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid × enasidenib × 90 days × Clear all
NCT05282459 2026-04-17

Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

Stanford University

Phase 1/2 Completed
17 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Leukemia, Monocytic, Acute, Leukemia, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡